|
(Ivanhoe Newswire) -- Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market, according to new data.
Led by Joseph Ross, MD, MHS, Assistant Professor of Geriatrics and Palliative Medicine at Mount Sinai School of Medicine, a team of six investigators analyzed 30 randomized, placebo-controlled trials of Vioxx.
"Independent, objective investigators can play a more active role in pharmaceutical safety surveillance, ideally in concert with the FDA and industry," Dr. Ross was quoted as saying. "Our study is an analytic approach that can be used to inform public health efforts. Comprehensive, rigorous analysis of clinical trial data allows the earlier identification of drug risks, promoting more informed treatment decisions, protecting the public's health, and perhaps saving lives."
Text Continues Below
The research team identified 30 randomized, placebo-controlled trials that enrolled a combined 20,152 individuals, and assigned participants to take doses of Vioxx ranging from 12.5 milligrams to 50 milligrams. Their analysis showed that safety concerns arose almost four years before the drug was withdrawn from the market. Dr. Ross and his colleagues found that as of December 2000 when 21 of the 30 studies had been completed there was strong concern that patients taking Vioxx were at a greater risk for cardiovascular conditions or blood clots.
Data through June 2001 showed Vioxx to be associated with a 35 percent increase in risk of a cardiovascular event or death. As of April 2002, the pooled analysis showed a 39 percent increased risk, and as of September 2004, a 43 percent increased risk.
Merck introduced Vioxx to the market in May 1999 and the drug quickly became a commercial success, with sales reaching $2 billion annually.
Dr. Ross and his colleagues performed their analysis in an effort to provide a blueprint for use of clinical trial data. The authors wrote, "Because the recently enacted FDA Amendments Act requires public disclosure of trial results within the ClinicalTrials.gov database within 12-24 months of study completion, including both efficacy and safety outcomes, clinical trial data should be available to conduct iterative meta-analyses independent of the FDA and manufacturers."
"Physicians and the public deserve to be in a position to make informed choices about risk and benefits [of pharmaceutical products]," they continued. "And the early disclosure and dissemination of information about potential risk after its recognition must be required."
SOURCE: Archives of Internal Medicine, November 23, 2009
If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com
This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.
|
.gif)
